Filing Details
- Accession Number:
- 0001144204-17-034719
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-06-28 21:00:00
- Reporting Period:
- 2017-06-26
- Filing Date:
- 2017-06-28
- Accepted Time:
- 2017-06-28 21:00:00
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1270073 | Intercept Pharmaceuticals Inc | ICPT | Pharmaceutical Preparations (2834) | 223868459 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1559569 | Mark Pruzanski | C/O Intercept Pharmaceuticals, Inc. 10 Hudson Yards, Floor 37 New York NY 10001 | Ceo & President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-06-26 | 40,000 | $8.67 | 611,718 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-06-26 | 7,816 | $129.49 | 603,902 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-06-26 | 18,763 | $130.46 | 585,139 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-06-26 | 5,893 | $131.18 | 579,246 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-06-26 | 5,485 | $132.54 | 573,761 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-06-26 | 2,043 | $133.07 | 571,718 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Options to Purchase Common Stock | Disposition | 2017-06-26 | 40,000 | $0.00 | 40,000 | $8.67 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
50,039 | 2020-08-16 | No | 4 | M | Direct |
Footnotes
- The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 20, 2017.
- All shares underlying this option have vested.
- This transaction was executed in multiple trades at prices ranging from $128.89 to $129.83. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $129.92 to $130.92. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $130.925 to $131.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $131.93 to $132.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $132.945 to $133.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.